Induction of cachexia in mice by Tisdale, M
Sir,
We have read with great interest the article by Cariuk et al
(Br J Cancer 1997 76: 606–613) entitled ‘Induction of cachexia in
mice by a product isolated from the urine of cachectic cancer
patients’. It is interesting to read about so-called cachexia-
inducing factor(s). The results obtained by Cariuk et al (1997) in
their exhaustive and well-designed study reveal that there is a
substance responsible for cachexia specifically occurring in cancer
patients.
As reported in their prepublished papers, they described a
proteoglycan of Mr 24 000, detected by Western blotting using
serum from mice bearing a cachexia-inducing tumour (MAC16),
which was present in the urine of patients with cancer cachexia but
absent from the urine of normal subjects (McDevitt et al, 1995;
Todorov et al, 1996). Significantly, this detected proteoglycan is
most likely a cachexia-inducing factor, according to the results
obtained from their studies in mice.
The authors have looked for the proteoglycan only in the urine
of the cachectic cancer patients, but not in the serum. They have
not taken the potential serum levels into account, which would be
more valuable. It is possible for such a proteoglycan to have
undergone renal metabolism or been affected by glomerular-
filtration rate, before it reaches the urine. It is interesting, and
somewhat questionable, to read that the proteoglycan capable of
inducing cachexia in mice and the one suspected of being respon-
sible for cachexia induction in humans are of the same molecular
weight. Moreover, Cariuk et al have isolated the former from the
serum but the latter from the urine. It is well known that the kidney
plays an important role in stabilization of the concentration and
turnover of oligopeptides and proteins in the extracellular fluid
matrix, and that it acts essentially as a passive barrier against loss
of intermediate and high molecular weight circulating proteins
(Johnson and Maack, 1989). This raises the question whether there
is a protein of higher molecular weight accompanying the proteo-
glycan of Mr 24000, described in the urine of cachectic cancer
patients, that has more significance in the aetiology of cachexia in
cancer patients and that is eliminated during its travel through the
kidney. Looking at the serum of such cachectic cancer patients
(instead of their urine) for isolation of proteins suspected of being
cachexia-inducing factors would not be difficult, but would help to
clarify this obscurity and would increase the value of the results
obtained by Cariuk et al (1997).
In addition, we would like to implicate the importance of mono-
clonal antibodies, produced against the factors that induce
cachexia, in the prevention of cachexia. Although they do not have
any positive effects on the treatment of the underlying cancer they
can be helpful in reducing the negative metabolic effects of
cachexia to the body.
I œ G￿ll￿ and S Marangoz, Hacettepe University, Institute of
Oncology, 06100 Sihhiye, Ankara, Turkey
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Sir,
It is certainly correct that the kidney plays an important role in main-
taining the concentration of proteins in the extracellular fluid. We
have utilized urine as the starting point for the purification for the
cachectic factor of Mr 24 000 (Cariuk et al, 1997) because the
kidney is so good at filtering out extraneous proteins, so that the
purification process is greatly simplified. The reason for not using
serum for the routine investigation of the cachectic factor is the low
abundance compared with other proteins present. Even in cachexia-
inducing tumours the factor represents just 40 ppb of the total
protein present (Todorov et al, 1996). This means that serum
requires extensive pre-purification of the factor before it can be
detected by Western blotting. However, we have no evidence that
either serum, or indeed solid tumours, inducing cachexia contain
higher molecular weights than the Mr 24 000 form found in urine.
The cachectic factor is a highly glycosylated sulphated glucoprotein
(Todorov et al, 1997), which is resistant to digestion by pronase,
trypsin, chymotrypsin or pepsin (Todorov et al, 1996). This may
explain its apparent stability in the body. Although monoclonal anti-
bodies to the factor attenuate the development of cachexia in exper-
imental systems, the road ahead for the treatment of cachexia
probably lies with low molecular weight inhibitors of the factor. One
such inhibitor, eicosapentaenoic acid (EPA: Lorite et al, 1997), has
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Sir,
Devon, Cornwall and the Isles of Scilly have had low standard
mortality rates (SMRs) for lung cancer for a number of years:
These low SMRs persist despite a smoking prevalence in the
peninsula that is no more than the national average (Torbay and
Plymouth Lifestyle Health Survey, 1993) and we have always
been doubtful about any major effect of radon on these rates. We
had looked forward to the results of the study by Darby et al (1998)
as likely to give a definitive answer to this matter, but were disad-
vantaged by having to comment publicly on a press release by the
authors in advance of the paper’s publication. Now that we have
read the paper we are concerned that the conclusions reached are
not justified by the data published in the article. In particular, since
the authors state in their conclusion: ‘although the confidence
intervals for these estimates just include zero, … the combined
evidence therefore suggests that a zero effect would not be an
appropriate interpretation of the study’s results’.
We are concerned that the public may be alarmed unnecessarily,
as it seems inappropriate to extrapolate the findings of other
studies done in very different circumstances to this particular
study. If, as seems likely, the authors are anticipating the outcome
of a meta-analysis of all these studies, which may demonstrate a
more definite link, then we would welcome this further research,
but it does not alter the findings from this study.
It would be helpful if the authors could comment on the points
giving us particular concern. Not surprisingly, most of them relate
to the ways in which the authors have sought to manage the effect
of smoking:
1. The exclusion of smoking-related diseases from the control
group leads to an under-representation of smokers in the
recently been shown to stabilize weight loss in patients with unre-
sectable pancreatic carcinoma (Wigmore et al, 1996).
M Tisdale, Pharmaceutical and Biological Sciences, Aston
University, Aston Triangle, Birmingham B4 7ET, UK
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Sir,
I was surprised to find an inconsistency in the data presented
recently by Brotherick et al 1998). In Figure 1C and D, the authors
show gated flow-cytometry histograms supposedly obtained from
gates applied to the data in Figure 1A. Close inspection of the data
on the x-axis, though, clearly indicates that Figure 1C and D were
not obtained from the data in Figure 1A. The peak of cells stained
with anti-oestrogen receptor antibody (anti-ER) for the cyto-
keratin-positive cells shown in Figure 1A would occur at approxi-
mately channel 1 ´ 101, whereas the alleged corresponding peak in
Figure 1C occurs at approximately channel 8 ´ 101. The same situ-
ation applies to the cytokeratin-negative cells shown in Figure 1D,
whose peak is at channel 1 ´ 101, even though it is clear that the
peak of anti-ER-stained cells in Figure 1A occurs far below
channel 1 ´ 101.
One explanation for this discrepancy is that different samples
may have been used in the preparation of this figure, instead of one
specific sample (as indicated in both the text and the legend).
Given this flaw, there is no convincing reason to trust the data
derived in Figure 2. Altogether, there are insufficient data to
support the authors’ concluding statement.
M Sheard
Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno,
The Czech Republic
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1994–1996 Cornwall and South and North and
SMR (95% CI) Isles of Scilly West Devon East Devon
Male 92 (85–99) 86 (80–92) 74 (68–81)
Female 79 (70–89) 90 (81–99) 64 (56–73)
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control group (Table 3 in Darby et al, 1998). Controls should
have been selected to represent those people who would have
been represented as cases had they developed the disease and
not to represent the entire non-diseased population (Rothman,
1986).
2. Tobacco consumption is estimated from reported smoking
habits only, which are known to under-report true smoking
status (Hill and Roberts, 1998). There is therefore a potential
mis-classification bias with the under-reporting of smoking
status greater in cases than controls, which is likely to lead to
an underestimation of the effect of smoking in cases.
3. There has been no attempt to measure passive smoking; since
the effect of radon is likely to be of the same order of magni-
tude as that of passive smoking, analysis of its effect would
appear essential in order to identify any additional effect of
radon.
4. While adjustment for smoking was made in seven categories,
only four appear in Table 11 (Darby et al, 1998), which
suggests that current smokers apparently have lower excess
relative risk than ex-smokers. This would appear to support
previous work indicating that many people stop smoking as
they become ill. Including recent ex-smokers with people who
stopped smoking more then 2–3 years ago would thus appear
inappropriate.
5. The authors have not demonstrated ‘little confounding
between radon and smoking status’ as stated in their discus-
sion. It is not clear that stratification is adequate when there
has been selection of controls according to the factor in ques-
tion. The question of effect modification between smoking and
radon is of great interest and not adequately answered by
including interaction terms within the model (Hill and Roberts,
1998). Residual confounding is particularly important if the
exposure has a weak effect.
6. The public health implications of this study are difficult to
interpret, as only a small proportion of cases and controls
(< 5% of each group) were exposed to levels of radon above
the threshold at which the NRPB currently recommends
remedial action (200 Bq m-3) and an even smaller proportion
of lung cancer cases (0.4%) were non-smokers.
Thus, in summary, we believe that differences between the
study and control groups, if real, could be explained by the inade-
quate measurement of tobacco-related behaviour in all the group.
As Directors of the local Public Health Departments who have to
deal with regular enquiries about radon, it will be difficult to give
any weight to the authors’ conclusions until we have further
comments.
D Miles1, J O￿Brien2 and M Owen3,
1Department of Public Health Medicine, Cornwall and Isles of
Scilly Health Authority; 2Department of Public Health Medicine,
South and West Devon Health Authority; 3Department of Public
Health Medicine, North and East Devon Health Authority, UK
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Sir,
We can sympathize with Drs Miles, O’Brien and Owen in their
puzzlement about the co-existence of relatively low standardized
mortality rates for lung cancer in Devon and Cornwall with the
high average levels of residential radon. This, however, is neither a
new phenomenon, nor even one limited to this country. A similar
negative association has been observed in the USA, leading some
to think that small doses of ionizing radiation might even be good
for you (Lubin, 1998). Interpretation of ecological data on the
effects of exposure to residential radon is complicated by the fact
that behavioural factors, particularly smoking, but also to some
minor extent diet, are so much more important a cause of lung
cancer. It is difficult to take these factors fully into account
because smoking has such a major effect, increasing the risk by
20-fold or more when cigarettes have been smoked consistently
for a long time, and the available data on the prevalence of
smoking by amount, type, sex and age are quite inadequate for the
purpose. Hence, it has been essential to make direct observations
on the effects of residential radon based on studies of individuals
and not just to rely on ecological correlations, or on extrapolations
made from the experience of miners who have been exposed to
similar, or somewhat greater, concentrations in very different
circumstances.
In interpreting the data from our own study, it would be bad
science to ignore all the other available information. In fact, it
would be making the same mistake as the tobacco industry made
when its representative claimed that passive smoking must be
harmless because one recent European study gave a lower 95%
confidence limit to the findings that just included a zero effect.
There have now been ten case-control studies of the relationship
between radon levels measured in homes and the risk of lung
cancer, and in combination they give results very similar to our
best estimate and to estimates from the experience of miners, as
we noted in our paper, and as shown below:
Increase in annual risk of
lung cancer per 100 Bq m–3 (%)
Estimates from miners +9
Meta-analysis of eight residential studies +9
Other residential studies
W Germany +13
SW England +8Letters to the Editor 1623
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Sir,
A recent study by Phillips et al (1998) describes a simple tissue
culture assay for investigating the extravascular penetration prop-
erties of anticancer drugs. The reported assay is a modification of
the method developed by ourselves (Cowan et al, 1996; Hicks et
al, 1997) and Minchinton et al (1997) in which tumour cells are
grown as multicellular layers (MCL) on commercially-available
Teflon microporous membranes. The ability of drugs to penetrate a
MCL separating two compartments can be investigated by adding
the compound of interest to the ‘donor’ compartment and
measuring its concentration in the ‘receiver’ compartment as a
function of time.
All these estimates should probably be increased by about 50%, as
shown in our paper, because of uncertainties in the measurement
of radon concentrations. As to the specific points that Drs Miles,
O’Brien and Owen make about our study, our response is:
1. Our controls were precisely those that ‘represent those people
who would have been represented as cases had they developed
the disease’ as half the group have been drawn at random from
the relevant population (matched for sex and age) and the
other half, the hospital controls (chosen to ensure that they had
the same smoking habits as the general population), had
almost identical smoking habits. The same result would have
been obtained if only general population controls had been
used, though with wider confidence limits, because of the
smaller amount of data.
2. There is no reason to think that the cases under-reported their
smoking habits more than the controls, because our findings
for the relative risk of lung cancer by smoking habit were
similar to, if not greater than, those recorded in unbiased
cohort studies.
3. Exposure to passive smoking was measured and is being
reported in a collaborative European study; it had no effect on
the results.
4. Table 11 in our original paper (Darby et al, 1998) shows the
increased relative risk with radon by smoking category. There
is no significant heterogeneity in the findings and they should
not be taken to imply that the risk is less for ex-smokers than
for current smokers. The much more extensive miners’ data
suggest that the increased relative risk is greater for non-
smokers than for smokers. While only four categories of
smokers are shown in the Table, our other three categories
(which relate to the amount smoked among current smokers
and the time since quitting among ex-smokers) are adjusted for
within current and ex-smokers as appropriate. The findings in
Table 11 have no bearing on the relative risk attributable to
smoking and do not support the idea that people stop smoking
when they become ill.
5. As mentioned in our paper, the crude increase in risk per
100 Bq m–3 is 0.05; this changes by only 0.03 to 0.08 after
adjustment for age, sex, county of residence and social class
as well as smoking. This demonstrates that there was little
confounding between radon and smoking status. Furthermore,
seven categories were used in the adjustment for smoking
status, and this level of stratification has been demonstrated on
the British doctors’ data to leave little residual confounding
(Breslow and Day, 1980).
6. The public health implications of our paper are quite clear:
a. it is much more important for smokers to stop smoking than
to do anything about the radon concentration in their home
b. regardless of smoking status, it is worth encouraging
people to have the radon concentration in their home
measured if they live in an area where the level is likely to
be above 200 Bq m–3 (the advised action level) and to take
action to reduce any high level if it is considered that an
increase in the risk of lung cancer of more than about
20–30% is a matter of public health concern
c. building regulations should be such as to ensure that radon
does not seep from underground into newly built houses
(which is not difficult to achieve), at least in areas where
the concentrations may be high.
Lastly, we note that Drs Miles, O’Brien and Owen would
welcome a meta-analysis of all available studies; this is in process.
Funding has been obtained from the European Union to undertake
a collaborative re-analysis of all 13 European studies currently
completed or underway and is being organized by our group in
Oxford. A similar collaborative re-analysis (superior to a meta-
analysis of published results) is being undertaken in North
America, after which it is hoped to merge the two sets of results. It
will, however, be some time before the results are available.
R Doll1, S Darby2, E Whitley2,3, P Silcocks2,4, B Thakrar2,5,
M Green6, P Lomas6, J Miles6, G Reeves2 and T Fearn7
1Clinical Trial Service Unit, University of Oxford, Harkness
Building, Radcliffe Infirmary, Oxford OX2 6HE, UK; 2ICRF
Cancer Epidemiology Unit, University of Oxford, Gibson
Building, Radcliffe Infirmary, Oxford OX2 6HE, UK;
3Department of Social Medicine, University of Bristol, Canynge
Hall, Whiteladies Road, Bristol BS8 2PR, UK; 4Trent Institute for
Health Services Research, Queens Medical Centre, Nottingham
NG7 2UH, UK; 5Glaxo Wellcome, Medical Data Sciences,
Greenford Road, Greenford, Middlesex UB6 0HE, UK; 6National
Radiological Protection Board, Chilton, Didcot, Oxon OX11
0RQ, UK; 7Department of Statistical Science, University College
London, Gower Street, London WC1E 6BT, UK
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The approach described by Phillips et al is similar to that used to
investigate drug penetration of Caco-2 monolayers, which model
the intestinal epithelial barrier (Adson et al, 1994). This method
differs from our own in several respects, both experimental and
analytical; some of these differences have important implications
if the intention is to understand transport in the extravascular
compartment of tumours, and thus warrant comment. Phillips et al
employ a Transwell vessel suspended in the well of a 24-well plate
to investigate penetration. An unstirred donor compartment of 100
ml is used above the MCL, and this vessel is transferred at intervals
to a new well containing stirred medium (600 ml) as the receiver
compartment. In contrast, our initial studies (Cowan et al, 1996;
Hicks et al, 1997, 1998) used an unstirred donor compartment of
500 ml (containing agar to prevent convective mixing) and a
stirred receiver compartment of at least 5 ml. As Phillips et al
point out, the smaller volumes in their system require less
compound, which we acknowledge as a distinct advantage.
The more important experimental difference is that in the
Phillips system the donor compartment, although not deliberately
stirred, does not contain a gelling agent such as agar to prevent
convective mixing. Phillips et al note that addition of agar ‘signif-
icantly reduces the rate of drug penetration’ in the absence of cells.
The effect of agar is almost certainly through its prevention of
mixing in the donor compartment, which will greatly facilitate
mass transfer. It would be impossible to avoid this artifact when
the vessel is moved between wells at frequent intervals, as in the
Phillips study. In fact the contribution of mixing to intercompart-
mental transfer is evident in the data presented. We have used
numerical methods (Hicks et al, 1997) to model the flux of tira-
pazamine due to diffusion in the absence of cells under the condi-
tions used by Phillips et al, using the diffusion coefficient of
tirapazamine in culture medium at 37°C (8.75 ´ 10–6 cm2 s–1; Hicks
et al, 1998). We assume that the microporous Teflon membrane
supporting the MCL is only 10 mm thick, with 100% porosity, and
that there are no unstirred boundary layers. Even with these
unrealistically favourable assumptions, the half-time for purely
diffusive transfer between an unstirred donor compartment of 100
ml and a stirred receiving compartment of 600 ml (in the absence of
an MCL) would be 30 min, whereas Figure 4 of Phillips et al
(1998) shows a half-time of approximately 5 min. Using these
same parameters but assuming efficient mixing in the donor
compartment gives slightly faster transfer (half-time 3.5 min) than
observed. It is thus probable that convective mixing in the donor
compartment in the Phillips assay is intermediate between the no-
mixing and fully mixed extremes. This gives a situation that is
impossible to model with precision.
But does the difficulty in extracting the underlying diffusion
parameters by modelling really matter? It could be argued that,
even if the extent of mixing is ill-defined, providing it is reason-
ably reproducible an appropriate rank ordering of compounds
could still be achieved. This brings us to a consideration of the
analytical approach taken by Phillips et al, which uses a compart-
mental model and characterizes mass transfer between the two
compartments as a first-order process. The parameter determined
is the half-time or first-order rate constant for transfer, which
would appear to provide a simple means for ranking compounds.
This approach is appropriate in the Caco-2 model, where the
objective is simply to quantitate mass transfer between compart-
ments. However, in the MCL model the objective is to infer, from
the net flux, the concentration gradient within the intervening
tissue compartment. This requires modelling the flux explicitly as
diffusion to extract the underlying transport parameters (diffusion
coefficient D and reaction rate constants), allowing use of the
same distributed parameter model to calculate pharmacokinetic
parameters within the extravascular compartment of a tumour. The
































































Figure 1 Hypothetical flux data (•) for a MCL (200 mm thick) with the donor
and receiver compartments (5 ml each) both well-stirred. The ordinate is the
concentration in the receiver as a percentage of that expected at equilibrium
(ignoring any loss due to reaction). Models are fitted, assuming a
homogeneous MCL, to a generalized reaction-diffusion equation: 
where D is the diffusion coefficient for free drug, kmet is the first order rate
constant for metabolism, k1 and k–1 are the forward and backward rate
constants for reversible binding, and c and cb are the concentrations of free
and bound drug respectively. The fitted parameters for the three models are
shown in Table 1
Figure 2 Simulated concentration-time curves in a tumour microregion
150 mm from blood vessels (——) for a drug that is cleared from plasma with
first-order kinetics (initial concentration 100 mM, half-life 30 min; – – –), using
the transport parameters for the three models fitted to MCL flux data in
Figure 1. The geometry is approximated as diffusion into a plane slab from
both sides, which is a compromise between radial inward and radial outward
diffusion. The calculated pharmacokinetic parameters for the central plane
are summarized in Table 1
¶c = D ¶2c – kmetc – k1c + k–1 cb ¶t ¶x2Letters to the Editor 1625
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difficult to use in vitro compartmental parameters to predict phar-
macokinetics within tissue, particularly since the experimental
half-life will be a function of thickness of the MCL (as noted by
Phillips et al) and will also depend on other details of the experi-
mental model. In contrast, diffusion parameters, if properly fitted,
are independent of these factors and can be applied directly to
describe the pharmacokinetics at any required position in the
extravascular compartment.
The importance of this becomes clearer with an example. Figure
1 shows hypothetical (but typical) MCL flux data for a drug in
culture medium using the diffusion chamber apparatus developed
in Minchinton’s laboratory (Kyle and Minchinton, 1998). In our
example the drug penetrates the MCL slowly, with a half-time for
intercompartmental transfer of about 24 h, but this value does little
to tell us whether the drug penetrates tumour tissue adequately. If
the flux is modelled explicitly as Fickian diffusion, then the slow
flux can be considered to result from (a) a low D in the MCL, (b)
irreversible reaction in the MCL (i.e. drug metabolism) or (c)
reversible reaction, such as non-covalent binding to immobile
macromolecules (e.g. binding of intercalators to DNA). There are
enough adjustable parameters in the binding models (Table 1) that
all three diffusion models fit the data equally well (similar sum of
squares) in this case. However, the three models have very different
implications for extravascular diffusion, as illustrated in Figure 2.
This shows the concentration-time profile for free drug in the centre
of a 300 mm-thick tumour region (simplified, planar geometry is
used in this example, but a qualitatively similar picture is obtained
with more realistic geometries), assuming a plasma half-life of 30
min. The pharmacokinetics in this microregion differ dramatically
depending whether the impediment to penetration in the MCL
comes from a genuinely low D, a higher D with metabolism
(reduced AUC) or a higher D with reversible binding (lowered
Cmax). The pharmacodynamic implications will also, of course, be
very different for the three situations, and will depend (amongst
other things) on whether there are threshold effects for the desired
biological responses. Measurement of flux across MCL cannot
easily distinguish these three extravascular transport models,
although metabolism results in a concave downwards flux curve,
while for reversible binding the curve is concave upwards because
flux speeds up as binding sites become filled. In some cases this
curvature is sufficient to make it obvious that binding or metabo-
lism is at work, as we illustrate in Hicks et al (1997, 1998) respec-
tively. However, in general it will be more reliable to constrain the
choice of models using independent information about the meta-
bolic and cell uptake/binding characteristics of the drug in question.
In the Phillips study the demonstration that transfer of EO9 has
a longer half-time for intercompartmental transfer than TPZ
(possibly limited by metabolism), but shorter than doxorubicin
(probably limited by reversible binding), cannot be used to draw
firm conclusions about the adequacy of its extravascular penetra-
tion properties. The observation that dicoumarol increases flux by
about 30% does suggest that penetration could be partially limited
by drug metabolism, and this might well compromise delivery to
cells distant from vessels. But an explicit reaction–diffusion model
is needed to enable predictions under typical in vivo conditions.
We fully concur with Phillips et al that drug penetration is an
important issue in cancer chemotherapy, and that experimental
models such as MCL can contribute to understanding this
problem, but it may be premature to conclude that poor penetration
of EO9 is responsible for its lack of activity in clinical trials. Such
an interpretation is not easy to reconcile with the anti-tumour
activity of EO9 in mice, including against human tumour
xenografts (Roed et al, 1989; Hendriks et al, 1993) and hypoxic
cells in the KHT tumour (Adams et al, 1992), despite a plasma
half-life threefold less in mice than humans.
The experimental model developed by Phillips et al has some
very attractive features in its miniaturization and convenience, and
could be adapted to overcome the above concerns by using either
agar in the donor compartment, or deliberate and efficient mixing
(as is used with the Caco-2 model). Any intermediate condition
will be difficult to reproduce, and is not amenable to modelling.
Extraction of the underlying transport parameters by modelling the
flux data is of fundamental importance in developing an under-
standing of the pharmacokinetics of anticancer agents in the
extravascular compartment of tumours.
WR Wilson and KO Hicks
Auckland Cancer Society Research Centre, The University of
Auckland, Private Bag 92019, Auckland, New Zealand
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Table 1 Fitted parameters for modelling of MCL flux (see Figure 1), and derived pharmacokinetic parameters for free drug at the centre of an extravascular
region in a tumour (see Figure 2)
Model Parameter values in the Pharmacokinetic parameters in
MCL used to model flux extravascular compartment
Dk met k1/k–1 Cmax
a Time to AUCt
b
(cm2 s–1) (min–1)( mM) Cmax (min) AUCp
(A) Simple diffusion 2.5 ´ 10–7 0 0 72.5 15 1.00
(B) Diffusion with first order  5 ´ 10–7 0.95 0 12.8 4 0.14
metabolism
(C) Diffusion with reversible  5 ´ 10–7 0 200 4.3 288 0.99
binding
aMaximum concentration. bAUC (area under the concentration-time curve) at the centre of the tumour microregion as a fraction of the plasma AUC.1626 Letters to the Editor
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Sir,
We read the article by Akslen and Sothern (1998) with interest; in
particular, the section concerning the presentation at clinic of the
cases with thyroid cancer where the authors note: ‘… significantly
more cases presenting during the late autumn and winter’. Without
disputing this finding, we would nevertheless like to point out how
this conclusion might be refined.
We first note that in a non-leap year and in the absence of any
seasonal effect, one would expect almost 11% more cases in
January, which has 31 days, than February, which has 28 days.
Thus the calendar month data given in Akslen and Sothern (1998,
Figure 1B) and reconstructed in Table 1 below, should be adjusted
to ‘months’ of equal duration which can be taken for convenience
as each of 30 days. This adjustment is carried out in two stages.
First, the number of observations in 31-day calendar months, such
as in each of the 16 January’s of the study period, are reduced by
(30/31), February increased by (30/28) in the 12 non-leap years
and by (30/29) in the 4 leap years.
The 30-day months, such as April, remain unadjusted. The
corresponding adjusted figures are given in column 3 of Table 1.
However, the frequencies in each 30-day month no longer sum to
the original 2627 patients. The second stage multiplies the
frequencies of column 3 by 2627/2595.98 = 1.01195 to account for
this. The adjustment clearly gives a greater emphasis to February
by increasing the count from 232 to 249.44 while decreasing those
of January and March.
These data can be illustrated graphically in a rose diagram
format (Figure 1) where each petal is of a ‘standard’ month or
360/12 = 30°. In this diagram, the square root of f is utilized to
preserve equal areas for each unit of frequency, as is the case for a
conventional histogram.
Seasonal variations in the presentation and growth of
thyroid cancer
Table 1 Monthly presentation of thyroid cancers (after Akslen and Sothern,
1998, Figures 1A and B)
Final
Number of First adjusted
Month Patients adjustment frequency
(n)a (f )
January 272 262.77 265.91
February 232 246.49 249.44
March 217 210.12 212.63
April 210 210.17 212.68
May 200 193.69 196.00
June 238 237.67 240.51
July 115 111.54 112.88
August 152 146.80 148.56
September 261 260.70 263.82
October 269 259.88 262.99
November 279 278.87 282.20
December 183 177.26 179.38
Total 2627 2595.98 2627.00


















Figure 1 Rose diagram of the monthly distribution of thyroid cancer. (The
hatched circle denotes the expected value per month if seasonality is absent)Letters to the Editor 1627
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Sir,
With regards to comments by Machin and Chong on our assign-
ment of number of cases of thyroid cancer to calendar month,
rather than to 12 equal intervals of the year (Akslen and Sothern,
1998), we are fully in concurrence that the latter would allow for a
more accurate comparison of seasonal patterns, since grouping
data solely by month may allow for slightly larger totals in months
with 31 days and slightly fewer in days with 30 days, or in
February with only 28 or 29 days. However, only month of diag-
nosis for the 2627 cases of thyroid cancer was entered from the
Norwegian Cancer Registry. The point of Machin and Chong is
well taken that careful records should be used in such epidemio-
logic studies in order to accurately detect and describe seasonal
and other predictable variations in disease, as shown in a recent
study on peptic ulcer (Svanes et al, 1998), where the results were
reported as incidence per month using 12 equal portions of the
year. In the latter study, we were also able to look at day of the
week and even clock time.
For analyses of the thyroid cancer incidence data, we assigned
monthly totals to the middle of each month. With the data so coded,
it was impossible to reassign some of the cases to another month,
except by such a method proposed by Machin and Chong which
adjusts the monthly totals proportionately. Regarding the grouping
of data by season, the choice of 3-month totals beginning with
Jan–Feb–Mar was somewhat arbitrary, since we were not able to
get actual ‘seasonal’ totals by beginning the first interval at the
Further improvement in the analysis can be made by utilizing
the actual dates of presentation of the patients with the thyroid
cancer, rather than merely using the corresponding month. This
more precise analysis, described by Machin and Chong (1998)
following the earlier suggestions of Mardia (1972), enables the
estimation of the peak date of presentation. If this approach is
applied (see Machin and Chong for details) to the grouped data of
Table 1, then the estimate of the peak date is 22 December (week
51). However, quoting the ‘day’ of peak here when using months
rather then the day as the unit for analysis may imply rather
spurious accuracy. The analysis based on individual dates also
allows estimation of a confidence interval (CI) for the peak date.
However, the method of calculation used for the CI depends both
on the sample size and the magnitude of the corresponding peak
(Fisher, 1993) and requires the individual dates of presentation.
Utilizing the grouped data and a bootstrap approach we obtained a
95% CI from 3 December to 10 January, but this is not likely to be
very reliable.
One rather unfortunate consequence of using monthly data is
then to test for the presence of seasonality by calculating a c2 test
with 11 degrees of freedom (df ). However, Newcombe (1983)
pointed out that this test only tests for departures from a uniform
distribution of cases throughout the year and not specifically for
the presence of a single peak. The test effectively compares each
frequency (n of Table 1) with its expected value; calculated under
the null hypothesis of a uniform distribution of cases throughout
the year. The authors obtained c2 = 119.3 with P < 0.00001 which,
although clearly statistically significant, does not imply that there
is therefore a (single) peak (date) of presentation.
A more appropriate test for the presence of a single peak has
been described by Mardia (1972; see Machin and Chong); this
utilizes the individual dates but can be calculated for grouped data
following the adjustments to the frequencies we have described in
Table 1. This c2 test has only 2 df and tests specifically for the
presence of a single peak in the data. For the data given here,
c2
Mardia = 38.01, df = 2 and P < 0.00001, and this provides clear
evidence of a (single) peak.
The definition of the (northern hemisphere) seasons used by
Akslen and Sothern (1998) are the four quarters of the year, thus
Winter is January, February and March. These ‘seasons’ differ
from those defined by, for example, Bounameaux et al (1996)
where Winter begins in December. This difference in season defi-
nition is one further difficulty that arises if data are grouped for
analysis and presentation. Such coarse groupings may make
comparisons between studies in different geographical locations
less meaningful.
In summary, although our assessment of these data has not
materially affected the conclusions of the authors, they do indicate
more precisely that the peak occurs in the December to January
period and the test we describe is specifically for that purpose. We
would reiterate Gilman et al (1998) and stress the importance of
the optimal use of the statistical techniques available if we are to
successfully identify aetiological factors that may be relevant to
the understanding of the disease in question.
D Machin1 and SF Chong1,2
1National Medical Research Council, Clinical Trials &
Epidemiology Research Unit, 10 College Road, Singapore
169851, 2Department of Clinical Research, Ministry of Health,
Singapore General Hospital, Singapore 169608
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Winter solstice (22 December); our data were assigned to the 15th
of each month (14th for February). We did group incidence data in
3-month segments beginning with Dec–Jan–Feb and actually got a
better chi-square result (c2 = 72.1) than we reported with intervals
beginning with Jan–Feb–Mar (c2 = 35.6), but the P-values were
< 0.0001 for each of these analyses. The use of the 3-month group-
ings beginning with Jan–Feb–Mar made sense for the area of the
world where the data were collected, which is subjected to large
changes in daylight throughout the year. During the seasons we
chose, the daylight is returning, but there is still more dark than
light each day (Jan–Feb–Mar), the daylight goes from half the day
to nearly the whole day (Apr–May–Jun), the amount of daylight
shortens to half the day (Jul–Aug–Sep), and the amount of daylight
decreases to nearly total darkness (Oct–Nov–Dec). It is clear that
seasonal patterns may not be easy to compare between hemispheres
and between studies using different 3-month spans, and we there-
fore emphasize the importance of also showing ‘monthly’ values
that are properly computed.
When we analysed our data several years prior to publication,
we were not aware of a newer technique to compute a time of peak
in incidence along with a confidence interval. It is true that such
data should be analysed by the ‘optimal … statistical techniques
available’, even though these authors state that their ‘assessment
of the data has not materially affected the conclusions of the
authors’, and we will be interested in learning about the technique
of Machin and Chong (1998) when it is published. We are familiar
with an earlier statistical procedure that tests for a peak in a time
series (Savage et al, 1962), but this is mostly used when a rhythmic
pattern is not pronounced and does not provide a confidence
interval. In a rhythmic time series, usually the peak of a cosine
model with the proper components to describe the waveform will
accurately locate the peak in the data (Tong et al, 1977), and this is
what we tried to do. However, periods harmonic to 1-year were not
significant for the incidence data, and consequently only the 1-
year cosine result was used. Of note, both our estimate of the
highest incidence and that of Machin and Chong, along with their
95% confidence interval, occurs in December, but inspection of
the monthly totals clearly shows a drop in incidence in December
and highest values in Sep–Oct–Nov. Therefore, we emphasized
that the highest incidence occurred in the late Fall–Winter, rather
than near a single date.
Finally, we wish to thank Machin and Chong for asking us for
the chance to apply their technique to our data. In so doing, we
found a coding error for the Jan monthly incidence total which
caused the graph in Figure 1B in our paper (Akslen and Sothern,
1998) to be in error in that the first dot at 274 should have been
graphed at 241. While c2 analyses and conclusions remain unal-
tered, the P-value for the 1-year cosine should have been given as
0.253, the mesor as 219 ± 12, the amplitude as 32 ± 17 and the
acrophase as 15 Dec in Table 1. We regret the error.
LA Akslen1 and RB Sothern2
1Department of Pathology, The Gade Institute, University of
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